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Background: Cutaneous melanoma is a malignant neoplasm with a constantly increasing incidence, the prognosis
of which is largely dependent on early diagnosis. The appropriateness of requests for ultrasound (US) tests during
melanoma follow-up of patients referred to our institute was evaluated.
Patients and methods: The requests for US tests of all patients referred to our institute over a four-month period
were assessed. In order to correctly evaluate the appropriateness of requests, patients were split into two groups on
the basis of melanoma thickness: > 1 mm (Group A) and < 1 mm (Group B).
Results: 546 patients were enrolled in our study out of a total of 1240 US tests performed. Out of 290 Group A
patients, 104 patients (35%) did not meet the established congruity criteria. Group B was composed of 256
individuals, 92 patients (35.9%) of which were found to have at least one inappropriate request.
Conclusion: In our study, more than 30% of the requests for US tests were found to be inappropriate, to the
detriment of those with a real need for diagnostic testing. This lengthens waiting lists and it may also increase
public healthcare costs. Therefore, it is mandatory to adopt new, widely accepted and easily applicable guidelines.
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Cutaneous melanoma is a malignant neoplasm with a
constantly increasing incidence [1], the prognosis of which
is still largely dependent on early diagnosis, which becomes
unfavorable at an advanced stage, regardless of treatment.
Therefore, melanoma follow-up requires periodical clin-
ical and instrumental tests which ought to be performed
with standardized protocols and at preset time intervals.
To this intent, many different solutions have been pro-
posed although widely accepted international guidelines
are still lacking. There are significant differences, as con-
firmed by a variety of national guidelines [2-6] whose
practical application in the clinical field is sometimes
limited because of poor compliance on the part of some
doctors and patients. For this reason, widely accepted* Correspondence: solivetti@ifo.it
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to regulate work-up of diagnostic-instrumental testing are
needed. This would lead to a reduction of the ever-
increasing costs for the healthcare system.
As a consequence, requests for inappropriate diagnostic
US tests during follow-up leads to a lengthening of waiting
lists, as well as a reduction of availability of US tests for
other important diseases, and first of all urgent tests.
Moreover, not only can the screening of patients with
excised low-risk lesion be considered unnecessary, but
also detrimental, because people suffer from more anxiety
about their health and can enter an endless loop of overdi-
agnosis, and possibly undergo overtreatment, a process
which does not promote health, but rather disease.
The aim of our study was to verify the appropriateness
of requests for the melanoma follow-up US tests performed
at our institute, a national public referral centre for derma-
tology and oncology.l Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Results related to the melanoma, the requests
and the US examinations in Patient Group A (melanoma
thickness > 1 mm) and Group B (< 1 mm)
Results Group A n =290 Group B n =256
N (%) N (%)
Site of melanomas 18 (6.2) 8 (3.1)
Head-neck 138 (47.6) 116 (45.3)
Upper torso 32 (11.0) 30 (11.7)
Lower torso 30 (10.3) 38 (14.8)
Upper Limbs 72 (24.8) 64 (25.0)
Lower Limbs
Sentinel Lymph node 228 (82.0) 2 (0.8)
Ulceration 20 (6.97) 0 (0)
Regression 2 (0.7) 2 (10.8)
Multiple melanoma 40 (13.8) 0 (0)
Familiarity 4 (1.4) 0 (0)
Mitosis 10 (3.4) 0 (0)
Urgent requests 16 (65.5) 4 (1.6)
Total US tests 644 596
Total unjustified US tests 206 (32.0)* 172 (28.9)*
Total cost (Euros) 21902.8 19979.6
Unjustified cost (Euros) 6709.4 (30.6)** 5704 (28.5)**
Note. * Out of total tests ** Out of total cost.
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The requests for US tests of all patients referred to our
institute for follow-up of malignant cutaneous melan-
oma, over a four-month period from July to October
2012, were assessed. Only those patients with complete
clinical records were enrolled in the study.
In order to obtain these data, a form was prepared in
advance for each single patient (Additional file 1).
Patients were split into two different groups on the
basis of melanoma thickness, that always proves critical,
either > 1 mm (Group A) or < 1 mm (Group B).
However, in the second group, we only considered ap-
propriate US requests for patients who meet one or
more of the following criteria [7] or risk factors:
– Presence of ulceration
– Number of mitoses > than 1 per mm2
– Regression
– Multiple or familiar melanoma
– Positive sentinel lymph node and/or in transit or
distant metastases
– Suspicious clinical data or instrumental reports.
The following were considered inadequate:
– Tests performed less than one month after an
analogous or similar previous negative test, unless
specific and motivated reasons were expressed in
the request;
– Tests performed more than five years after initial
diagnosis, without any evidence of recurrence of
disease or new melanoma during this period [8];
– Tests relative to melanoma in situ or < 1 mm
not meeting Group B inclusion criteria, as
previously listed;
– Tests indicating lymph nodes stations at a
non-plausible anatomical site of drainage, in the
absence of any significant objective evidence.
Furthermore, before performing US tests, patients were
asked to self-assess their approach to testing, with special
attention to their mood (i.e. anxiety, mistrust), and
also to its usefulness according to a VAS (Visive Ana-
logic Scale) score ranging from 0 (excessive or inad-
equate) to 100 (very useful). These data were included
in the form.
Finally, given the limitations associated with the fre-
quent need for long-term planning of investigations, in
relation to planned follow-up visits, we calculated the
time interval between the date of request and the date
on which it was actually performed.
About 10% of US requests examined were excluded
from the study for incomplete clinical and instrumental
data obtained.Statistical methodology
All results were reported with frequencies and medians;
the associations were estimated using the Chi-squared
test or Fisher’s Exact, when appropriate. The comparison
between the two groups of interest was evaluated using
the Mann–Whitney test. All the analyses were performed
utilizing SPSS statistical software. (SPSS, Chicago, Il, U.S.A.;
Version 20.0).
Results
The final study population was composed of 546 pa-
tients, respectively 277 females (50.7%) and 269 males
(49.3%). The length of follow-up of these patients was
37 months (median time), with a mean of 2.3 tests per-
formed per individual patient. A total number of 1240 US
tests were performed over four months. The cost of these
exams, borne by the national health care system, amounted
to 41,882 Euros. Out of 1240, 378 requests (30.5%) were in-
appropriate. Results related to tumor localization and final
study population characteristics are extensively reported in
Tables 1, 2.
Out of 546 patients, Group A comprised 290 individ-
uals (53.1%) (melanoma thickness > 1 mm), and Group
B comprised 256 individuals (46.9%) (melanoma thick-
ness < 1 mm) (Figure 1).
In Group A, the median age was 58 years, while in
Group B it was 52 years. Waiting time for Group A
Table 2 Characteristics of the final study population
(n = 546) split into two groups [Group A (melanoma






Sex n(%) n(%) 0.88
M 148 (51.0) 129 (50.4)






Age (years) 58 (18–86) 52 (26–81) 0.004
Waiting Time (months) 28.7 (0–86) 7 (0–63) 0.05
Time between US tests (months) 12.4 (0–37) 9 (0–74) < 0.0001
US tests/patients (N) 2 (0–5) 2 (0–6) 0.19
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63 days, whereas for Group B, average waiting time was
28.7 days, with a range of 0–86 days.
In the case of repeated tests, the interval between each
test for Group A patients was 12.4 months on average ,
with a range of 0–37 months, whereas 9.3 months, with
a range of 0–74 months was reported for Group B.
As for costs and test appropriateness: a total of 644
tests were performed in Group A (290 patients). In this
group, 104 patients were found to have an inappropriate
motivation (35.9%), for a total of 206 unjustified exami-
nations (32%). Consequently, for this group there was a
cost of 6,709 Euros for unjustified tests out of a total of
21,902 Euros.
596 tests were performed in Group B, formed of 256
individuals. In this group, 92 patients with at least one
unjustified request (35.9%), and a total of 172 unjustified
tests (29%) were reported. Consequently, 5,704 EurosFigure 1 Inappropriated test according to tumor localization
for patients of Group A and Group B.was spent for unjustified tests out of a total cost of
19,976 Euros.
It is interesting to note that the percentage of unjustified
tests is similar in the two groups (32% for Group A vs.
29% for Group B, p = 0.53), although for different reasons.
In fact, the most common among the unjustified requests
in Group A was a test prescribed after more than 5 years
(62.5%), whereas in Group B there were two main causes,
the excessively long follow-up (35.6%) and incorrect indi-
cation of the lymph node station (37.8) (Figure 2).
Moreover, on the basis of patients’ perception, test use-
fulness was deemed very high since 97% of them expressed
a satisfaction rate equivalent to the maximum VAS score.
In a subgroup of melanoma in situ (N = 81 patients,
13.5%), identified as part of Group B, further thorough
exams were requested for 11 patients because of the in-
cidental discovery of seven large hepatic angiomas, two
adrenal adenomas, a complex renal cyst and a pancreatic
pseudocyst, all irrelevant in relation to evolution of the
clinical outcome as well as expensive for the national
healthcare system and stressful for the patients. We found
less percentages of “incidentalomas” in the other Sub-
group B (5%) and Group A (12%).
Discussion
According to our data, about 30% of US tests are in-
appropriate, which represents a high percentage if we
consider these requests came from expert oncologists
and dermatologists at our institute.
Since the total cost for US tests performed in our insti-
tute amounted to 41,882 Euros over a four-month period,
the total cost per year could be estimated at 125,646 euro;
of these, unjustified US tests had a charge of 12,413 Euros
(6,709 Euros for Group A + 5704 Euros for Group B) for a
four-month period, estimated at 37,239 Euros over a year
(the unjustified expense for the institute is about the 30%
of the total cost).Figure 2 Reasons for Inappropriateness for patient both Group
A and Group B.
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the year 2000 – the last available global data – the annual
rate of US tests performed by Italian National Health Ser-
vice facilities was 17.4 per 100 inhabitants [9]; conse-
quently in order to evaluate such an economic burden for
the whole country, we can estimate 30 million US tests
performed per year (adding to them diagnostic tests car-
ried out during hospitalization and by private health facil-
ities, paid entirely by patients). This number is bound to
increase in the following years, considering the further
spread of the method and the improving technology that
make it possible to include US tests in oncologic follow-
up routines. If these values are related to the percentage
of erroneous requests found in our study (about 30%), it is
possible to assume that about 10,000,000 unnecessary U.S.
tests may be performed in Italy per year.
They represent an enormous cost for our society which
is no longer acceptable. It is also correct to say that an un-
justified test could lead to further diagnostic tests which
are not beneficial in relation to the underlying disease,
and increase costs even more.
On the other hand, the appropriate use of complemen-
tary diagnostic tests during follow-up for melanoma could
reduce costs related to patient management for this dis-
ease [10].
The relevant percentage of mistakes in identifying the
lymph node station, that in our case studies shows an
error rate of 32% for lesions of thickness > 1 mm and
29% for those < 1 mm [11], should also be underlined.
The percentage of error is greater for the numerous re-
quests for examination of multiple stations. They are
certainly greater in number than those correctly exam-
ined, due to the practice of “defensive medicine”, which
is the main cause of too long, if not totally unnecessary
follow-ups, such as for melanomas in situ - stage 1a.
The waiting list in our institute is much shorter than
the national one, the data obtained from our series is
marred by an intrinsic enrollment bias; in fact, the re-
quests for US tests are often spontaneously postponed
by the patient, or sometimes also by the doctor who defers
them until the scheduled oncological follow-up. However,
it must be stressed that the need to meet all these inappro-
priate demands unfortunately results in a lengthening of
waiting lists for other patients with obvious repercussions
on public health.
From a patient viewpoint, it is important to underline
the great degree of satisfaction of patients undergoing
US tests for follow-up and the placebo effect generated
by a favorable prognosis. The majority of these patients,
regardless of the initial diagnosis, considered the exam-
ination of the utmost importance and were determined
to undergo it even if their personal approach to the test
was characterized by different moods; only 3% of pa-
tients considered follow-up imaging no longer usefuland reported their unwillingness to undergo clinical
check-ups because of a deep state of anxiety. Although
there are no studies in this direction, the damage caused
to patients as a result of unnecessary testing should be
emphasized; harm related to the loss of working days,
transfer expenses, and especially stress related to the ex-
pectation and execution of the examination. The same
stress may also be the indirect cause of the high value
assigned by our oncological patients to the examination
itself, thus triggering dangerous feedback.
In our opinion this problem could be significantly re-
duced by creating new referral pathology centers where
physicians are able to carry out correct work-up of the
patients, share clinical data and establish complete com-
puterized centralization of requests with an updated list
of all the diagnostic, as well as therapeutic procedures
performed, along with their final outcome also in order
to reduce unnecessary/harmful repetition of the same
diagnostic tests. Furthermore, we hope for strict compli-
ance with existing guidelines, or the creation of new,
universally accepted guidelines that provide better clin-
ical and legal justification of the timing and nature of
diagnostic tests required for the follow-up of melanoma,
and consequently reduce the problem of defensive medi-
cine emerging in Italy’s medical-legal framework.
Conclusion
To conclude, it is clear that about 30% of the US diag-
nostic examinations performed are unjustified according
to the general guidelines currently in use. Therefore, they
have not been requested according to strict clinical scien-
tific parameters, but for other reasons, possibly medical-
legal ones.
Thus, there is need for the adoption of new shared,
widely accepted and easily applicable guidelines, also in
light of other considerations related to health costs and
medical-legal aspects.
Given that said issues represent a thorny issue for other
referral centers, we consider it absolutely necessary to up-
date existing guidelines to make for easier use by special-
ists as well as General Practitioners.
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